Frederick L. Locke

Frederick L. Locke

H. Lee Moffitt Cancer Center & Research Institute - Tampa / United States
Others
AD Scientific Index ID: 4918557
person_outline Frederick L. Locke's MOST POPULAR ARTICLES
1-) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphomaSS Neelapu, FL Locke, NL Bartlett, LJ Lekakis, DB Miklos, CA Jacobson, ...New England Journal of Medicine 377 (26), 2531-2544, 201735832017
2-) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cellsDW Lee, BD Santomasso, FL Locke, A Ghobadi, CJ Turtle, JN Brudno, ...Biology of blood and marrow transplantation 25 (4), 625-638, 201919792019
3-) Chimeric antigen receptor T-cell therapy—assessment and management of toxicitiesSS Neelapu, S Tummala, P Kebriaei, W Wierda, C Gutierrez, FL Locke, ...Nature reviews Clinical oncology 15 (1), 47-62, 201819532018
4-) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trialFL Locke, A Ghobadi, CA Jacobson, DB Miklos, LJ Lekakis, OO Oluwole, ...The lancet oncology 20 (1), 31-42, 201920782019
5-) KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphomaM Wang, J Munoz, A Goy, FL Locke, CA Jacobson, BT Hill, ...New England journal of medicine 382 (14), 1331-1342, 202015332020